Lauxera Capital Partners closed its second healthtech fund at €520M, reaching its target in under 18 months. The growth-stage vehicle follows the firm’s debut fund, which launched in 2021, and focuses on scaling European health technology businesses that have reached commercial maturity.
Based in France, Lauxera Capital Partners invests in companies developing medical devices, digital health tools, and life sciences software. The firm targets businesses with proven clinical utility and existing revenue, providing the capital necessary to expand across European markets and into the United States.
The fundraise highlights a robust appetite for specialised healthtech investment despite a broader slowdown in venture activity. Lauxera’s strategy centres on the "commercial valley of death," assisting European founders in navigating complex regulatory environments and multi-country reimbursement systems that often stall growth at the scale-up phase.
This significant capital pool reinforces France’s position as a primary hub for European healthtech, where deep-tech specialisation is increasingly met with the growth equity required to build global champions.
Originally reported by Tech Funding News.